ClinicalTrials.gg
CompletedNCT04202068CRO-SBTUpdated Dec 17, 2019

A Study Evaluating Efficacy and Safety of CRO-SBT in the Treatment of Gonorrhea

A Phase 4 interventional study of Ceftriaxone sodium and Sulbactam Sodium for injection in Gonorrhea, sponsored by Xiangbei Welman Pharmaceutical Co., Ltd. Completed. Open to participants aged 6 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-12-17.

Sponsored by Xiangbei Welman Pharmaceutical Co., Ltd · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 5 months after the study started (first participant enrolled Jul 2015, registered Dec 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
113
Allocation
Not applicable
Ages
6 Years to 80 Years
Sex
All
01

Study summary

This is a phaseIV, multicenter, open-label,single arm study which will be performed to evaluate efficacy and safety of Ceftriaxone sodium and Sulbactam Sodium for injection for the treatment of uncomplicated urogenital infection caused by Neisseria gonorrhoeae in adolescent and adult subjects.

Read the detailed description

In this study, adults will be administered as one 3g IV dose at the study site,Children under 12 will be administered as one 75mg/kg IV dose . Approximately 100 subjects will be recruited to receive study treatment. The duration of the study will be approximately 14 days.

02

Conditions studied

  • Gonorrhea

Browse trials for

03

In context

Gonorrhea

168 studies on the registry are indexed under Gonorrhea; 32 are open to participants now.

This study's enrollment of 113 is below the median of 380 across 126 interventional studies indexed under Gonorrhea.

Browse Gonorrhea studies →

Lead sponsor

Xiangbei Welman Pharmaceutical Co., Ltd is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be >=6 or ≦80 years of age at the time of signing the ,both gender
  • Subjects having clinical suspicion of a urogenital gonococcal infection with or without gonococcal infection according to the laboratory test results of symptoms, physical symptoms, gonococcus smear, culture, etc.
  • Subjects having clinical suspicion of a gonococcal infection must have both of the following risk factors:once used three generations of cephalosporin invalid, and sensitive to this product (including gonorrhea urethritis, cervicitis, proctitis, pharyngitis).
  • Male and female subject must agree to use (male condoms) during intercourse from the Baseline Visit through completion of the TOC Visit.

Exclusion criteria

Exclusion Criteria:

  • Subject has a history of sensitivity to the study treatments, or components thereof, or a history of a drug (including erythromycin and any macrolide or ketolide drug) or other allergy that, in the opinion of the investigator or medical monitor, contraindicates his or her participation
  • Subject has received any cephalosporinl therapy for the treatment of a gonococcal infection
  • Pregnant or lactating women, or women Subject of childbearing age who were unwilling or unable to use acceptable methods of throughout the study period.
  • Famale subject who were positive for pregnancy tests at the time of inclusion or before the start of study drug use.
  • Subject has risk of potentially serious drug interactions
  • Subject has major diseases such as cardiovascular disease, hepatorenal disease and mental disease, or other factors, the researcher should not participate in the study according to comprehensive judgment
  • Subject has a known history of alcohol or drug abuse
  • Subject has a known any complicated or systemic gonorrhea infection, such as pelvic inflammatory disease, arthritis, endocarditis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Ceftriaxone sodium and Sulbactam Sodium for injection

    combinations of β-Lactamase inhibitors

    Drug: Ceftriaxone sodium and Sulbactam Sodium for injection

Interventions

  • DrugCeftriaxone sodium and Sulbactam Sodium for injection

    Drug pages: Ceftriaxone · Sulbactam

    Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.

    Also known as: CRO-SBT

06

What researchers measure

Primary outcomes

  1. bacterial eradicatio

    Number of subjects with culture-confirmed bacterial eradication of Neisseria gonorrhoeae from the urogenital site at the Test-of-Cure (TOC)

    Time frame: Up to Day 8

Secondary outcomes

  1. clinical cure

    Number of subjects with disappearance of clinical symptoms and signs at the Test-of-Cure (TOC)

    Time frame: Up to Day 8

  2. Comprehensive curative effect

    Number of subjects with culture-confirmed bacterial eradication of Neisseria gonorrhoeae from the urogenital site and disappearance of clinical symptoms and signs

    Time frame: Up to Day 8

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2015 to primary completion in May 2016, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2019
First posted
Dec 17, 2019
StartActual
Jul 3, 2015
Primary completionActual
May 3, 2016
CompletionActual
May 30, 2016
Last update
Dec 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04202068
Lead sponsor
Xiangbei Welman Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Dec 17, 2019
Start date
Jul 3, 2015
Primary completion
May 3, 2016
Completion
May 30, 2016
Last update
Dec 17, 2019

Study contacts

pingyu P Zhou, Doctor
principal investigator · Shanghai Dermatology Hospital
shunming S Xu, Doctor
principal investigator · People's Hospital of Shanghai Pudong New Area
yanyue Tong, Doctor
principal investigator · People's Hospital of Quzhou
zhehu Jin, Doctor
principal investigator · The Affiliated Hospital of Yanbian University
bo Cheng, Doctor
principal investigator · First Affiliated Hospital of Fujian Medical University
wuqing W Wang, Doctor
principal investigator · The Central Hospital of Shanghai Minhang District
ping Wang, Doctor
principal investigator · The Third People's Hospital of Hangzhou

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ceftriaxone · Sulbactam

Start the discussion